Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8071 to 8085 of 8965 results

  1. Atopic Dermatitis (Eczema)

    Discontinued Reference number: GID-NG10289

    NICE guideline
    Discontinued

  2. Workplace health for employees with disabilities and long-term conditions

    Discontinued Reference number: GID-PHG58

    NICE guideline
    Discontinued

  3. Preterm labour and birth - timing of cord clamping

    Discontinued Reference number: GID-NG10396

    NICE guideline
    Discontinued

  4. Preterm labour and birth - predicting preterm birth

    Discontinued Reference number: GID-NG10384

    NICE guideline
    Discontinued

  5. Intrapartum care for healthy women and babies - angle of episiotomy

    Discontinued Reference number: GID-NG10394

    NICE guideline
    Discontinued

  6. Haemochromatosis

    Discontinued Reference number: GID-NG10287

    NICE guideline
    Discontinued

  7. Type 2 diabetes in adults: management - insulin therapy

    Discontinued Reference number: GID-NG10375

    NICE guideline
    Discontinued

  8. Personal, social, health and economic education focusing on sex and relationships and alcohol education

    Discontinued Reference number: GID-PHG0

    NICE guideline
    Discontinued

  9. Workplace health - older employees

    Discontinued Reference number: GID-PHG59

    NICE guideline
    Discontinued

  10. Blepharitis: antimicrobial prescribing

    Discontinued Reference number: GID-NG10168

    Antimicrobial prescribing guideline
    Discontinued

  11. Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]

    In development Reference number: GID-TA10684 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Iptacopan for treating complement 3 glomerulopathy in people 12 to 18 years [ID6738]

    In development Reference number: GID-TA11913 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Sacituzumab govitecan with pembrolizumab for untreated metastatic non-small-cell lung cancer with a PD-L1 expression of 50% or more [ID6739]

    In development Reference number: GID-TA11880 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Ultra-radical (extensive) surgery for advanced ovarian cancer (IPG470)

    This guidance has been updated and replaced by NICE HealthTech guidance 668.

    Withdrawn guidance

  15. Rocatinlimab for treating moderate to severe atopic dermatitis in people 12 years and over [ID6565]

    In development Reference number: GID-TA11759 Expected publication date: TBC

    Technology appraisal guidance
    In development